|
|
|
Volumn 33, Issue 6, 2008, Pages
|
|
Implementing antiobesity treatment in a patient with a mood disorder
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMFEBUTAMONE;
ANTIOBESITY AGENT;
ATYPICAL ANTIPSYCHOTIC AGENT;
CYTOCHROME P450 3A4;
ESCITALOPRAM;
GLUCOSE;
LITHIUM;
PAROXETINE;
SEROTONIN UPTAKE INHIBITOR;
SIBUTRAMINE;
TETRAHYDROLIPSTATIN;
TOPIRAMATE;
ABNORMAL FECES;
ADULT;
AGITATION;
ARTICLE;
BIPOLAR DISORDER;
BODY MASS;
CANADA;
CASE REPORT;
COGNITIVE DEFECT;
DIET RESTRICTION;
DIET THERAPY;
DIETITIAN;
DRUG CONTRAINDICATION;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG RESPONSE;
DRUG SUBSTITUTION;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
DYSLIPIDEMIA;
FEMALE;
GASTROINTESTINAL SYMPTOM;
GLUCOSE BLOOD LEVEL;
HUMAN;
LIFESTYLE MODIFICATION;
MOOD DISORDER;
OBESITY;
PATIENT MONITORING;
PATIENT REFERRAL;
PHYSICAL ACTIVITY;
RISK BENEFIT ANALYSIS;
SIDE EFFECT;
WEIGHT GAIN;
ADULT;
ANTI-OBESITY AGENTS;
ANTIDEPRESSIVE AGENTS;
ANTIMANIC AGENTS;
APPETITE DEPRESSANTS;
CYCLOBUTANES;
FEMALE;
HUMANS;
LIFE STYLE;
MOOD DISORDERS;
OBESITY;
|
|
EID: 56349117634
PISSN: 11804882
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (6)
|
